NICE approves natalizumab for multiple sclerosis

NICE has published an appraisal of the use of natalizumab in the treatment of adults with highly active relapsing-remitting multiple sclerosis.

Key recommendations:

  • Treatment is recommended only for the treatment of rapidly evolving severe relapsing-remitting multiple sclerosis (e.g. patients with two or more disabling relapses in a year and who have an active MRI scan).
  • Patients currently receiving natalizumab, but for whom treatment would not have been recommended (see above), may continue therapy until they and their clinicians consider it appropriate to stop.


The full guideline is available at www.nice.org.uk.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus